Increase in geriatric population, rise in funding from private-public organizations for cardiac biomarkers research, and ongoing research and clinical trials for identification of the newer cardiac biomarkers are the key factors boost the congestive heart disease marker tests market over the forecast period. Moreover, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing, and increase in the adoption of new diagnostic tools by healthcare professionals and cost affordability for patients might propel the global congestive heart disease marker tests market over the forecast period. A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-congestive-heart-disease-marker-tests-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
The congestive heart disease marker tests market is segmented on the basis of product type, test type, application, and end-user
Based on product type, the congestive heart disease marker tests market has been segmented into the following:
Reagents
Kits
Instruments
Chemiluminescence
Immunofluorescence
ELISA
Immunochromatography
Based on test type, the congestive heart disease marker tests market has been segmented into the following:
Myocardial muscle Creatine Kinase (CK-MB)
Myoglobin
Troponins (T and I)
Ischemia Modified Albumin (IMA)
NT-proBNP or Brain Natriuretic Peptide (BNP) or
Others
Based on application, the congestive heart disease marker tests market has been segmented into the following:
Myocardial Infarction
Acute Coronary Syndrome
Congestive Heart Failure
Atherosclerosis
Others
Based on the end-user, the congestive heart disease marker tests market has been segmented into the following:
Hospitals
Clinics
Diagnostic Centres
Others
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-congestive-heart-disease-marker-tests-market/#ulp-c654SbFYO64MsOhu[/URL]
Launch of new products, technological advancements, acquisitions and mergers, and collaborations are some key strategies followed by various industry players to increase their share in the congestive heart disease marker test market. For instance, in July 2011, Thermo Fisher Scientific it inked a license agreement with Alere Inc. to develop its novel Thermo Scientific B.R.A.H.M.S. biomarker assays on Alere’s leading point-of-care Triage platform.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-congestive-heart-disease-marker-tests-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in congestive heart disease marker test market are F. Hoffmann-La Roche (Switzerland), Siemens AG (Germany), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Nanogen, Inc. (U.S.), bioMérieux SA (France), Alere, Inc. (U.S.), LSI Medience Corporation (Mitsubishi Chemical Holdings Corporation, Japan), Randox Laboratories Ltd (U.K.), Ortho Clinical Diagnostics (The Carlyle Group) (U.S.),and Guangzhou Wondfo Biotech Co. Ltd. (China) to name a few.
"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553"